Ohio Admin. Code 4715-6-01 - Standards and procedures for review of "Ohio Automated Rx Reporting System" (OARRS)
(A) Definitions: for the purposes of this
rule:
(1) "Delegate" means an authorized
representative who is registered with the Ohio board of pharmacy to obtain an
OARRS report on behalf of a dentist;
(2) "OARRS" means the "Ohio Automated Rx
Reporting System" drug database established and maintained pursuant to section
4729.75 of the Revised
Code.
(3) "OARRS report" means a
report of information related to a specified patient generated by the drug
database established and maintained pursuant to section
4729.75 of the Revised
Code.
(4) "Personally furnish"
means the distribution of drugs by a prescriber to the prescriber's patients
for use outside the prescriber's practice setting. Personally furnish does not
include the administration of a drug, k as
set forth in paragraph (B)(1) of rule
4715-3-01 of the Administrative
Code.
(5) "Reported drugs" means
all the drugs listed in rule 4729-37-02
4729:8-2-01 of the Administrative Code that are
required to be reported to the drug database established and maintained
pursuant to section 4729.75
sections
4729.77,
4729.78 and
4729.79
of the Revised
Code, including;
controlled substances in schedules II, III, IV, and
V.
(a)
All
schedule II controlled substances;
(b)
All schedule III
controlled substances;
(c)
All schedule IV controlled substances;
(d)
All schedule V
controlled substances.
(B) Standards of care: the accepted and
prevailing minimal standards of care require that when prescribing or
personally furnishing a reported drug, a dentist shall take into account all of
the following:
(1) The potential for abuse of
the reported drug;
(2) The
possibility that use f the reported drug may lead to dependence;
(3) The possibility the patient will obtain
the reported drug for a nontherapuetic use or distribute it to other persons;
and
(4) The potential existence of
an illicit market for the reported drug.
(5) In considering whether a prescription for
or the personally furnishing of a reported drug is appropriate for the patient,
the dentist shall use sound clinical judgment and obtain and review an OARRS
report consistent with the provisions of this rule.
(C) OARRS Review: a dentist shall obtain and
review an OARRS report to help determine if it is appropriate to prescribe or
personally furnish an opioid analgesic, benzodiazepine, or reported drug to a
patient as provided in this paragraph and paragraph (F) of this rule:
(1) A dentist shall obtain and review an
OARRS report before prescribing or personally furnishing an opiate analgesic or
benzodiazepine to a patient, unless an exception listed in paragraph (G) of
this rule is applicable.
(2) A
dentist shall obtain and review an OARRS report when a patient's course of
treatment with a reported drug other than an opioid analgesic or benzodiazepine
has lasted more than ninety days, unless an exception listed in paragraph (G)
of this rule is applicable.
(3) A
dentist shall obtain and review an OARRS report when any of the following red
flags pertain to the patient:
(a) Selling
prescription drugs;
(b) Forging or
altering a prescription;
(c)
Stealing or borrowing reported drugs;
(d) Increasing the dosage of reported drugs
in amounts that exceed the prescribed amount;
(e) Suffering an overdose, intentional or
unintentional;
(f) Having a drug
screed result that is inconsistent with the treatment plan or
(g) Having been arrested, convicted, or
received diversion or intervention in lieu of conviction for a drug related
offense while under the dentist's care;
(h) Receiving reported drugs from multiple
prescribers, without clinical basis;
(i) Traveling with a group of other patients
to the dentist's office where all or most of the patients request controlled
substance prescriptions;
(j)
Traveling an extended distance or from out of state to the dentist's
office;
(k) Having a family member,
friend, law enforcement officer, or health care professional express concern
related to the patient's use of illegal or reported drugs;
(l) A known history of chemical abuse or
dependency;
(m) Appearing impaired
or overly sedated during an office visit or exam;
(n) Requesting reported drugs by street name,
color, or identifying marks;
(o)
Frequently requesting early refills of reported drugs;
(p) Frequently losing prescriptions for
reported drugs;
(q) A history of
illegal drug use;
(r) Sharing
reported drugs with another person; or
(s) Recurring visits to non-coordinated sites
of care, such as emergency departments, urgent care facilities, or walk-in
clinics to obtain reported drugs.
(D) Patient care documentation: a dentist who
decides to utilize an opioid analgesic, benzodiazepine, or other reported drug
in any of the circumstances within paragraphs (C)(2) and (C)(3) of this rule,
shall take the following steps prior to issuing a prescription for or
personally furnishing the opioid analgesic, benzodiazepine, or other reported
drug:
(1) Review and document in the patient
record the reasons why the dentist believes or has reason to believe that the
patient may be abusing or diverting drugs;
(2) Review and document in the patient's
record the patient's progress toward treatment objectives over the course of
treatment;
(3) Review and document
in the patient record the functional status of the patient, including
activities for daily living, adverse effects, analgesia, and aberrant behavior
over the course of treatment;
(4)
Consider using a patient treatment agreement including more frequent and
periodic reviews of OARRS reports and that may also include more frequent
office visits, different treatment options, drug screens, use of one pharmacy,
use of one provider for the prescription or personally furnishing of reported
drugs, and consequences for non-compliance with the terms of the agreement. The
patient treatment agreement shall be maintained as part of the patient record;
and
(5) Consider consulting with or
referring the patient to a substance abuse specialist.
(E) Follow-up OARRS reports; frequency:
(1) For a patient whose treatment with an
opioid analgesic or benzodiazepine lasts more than ninety days, a dentist shall
obtain and review an OARRS report for the patient at least every ninety days
during the course of treatment, unless an exception listed in paragraph (G) of
this rule is applicable.
(2) For a
patient who is treated with a reported drug other than an opioid analgesic or
benzodiazepine for a period lasting more than ninety days, the dentist shall
obtain and review an OARRS report for the patient at least annually following
the initial OARRS report obtained and reviewed pursuant to paragraph (C)(2) of
this rule until the course of treatment utilizing the reported drug has ended,
unless an exception in paragraph (G) of this rule is applicable.
(F) OARRS reports; time periods;
adjoining states: for the purposes of paragraphs (C), (D), and (E) of this
rule, when a dentist or their delegate requests an OARRS report in compliance
with this rule, a dentist shall review and document receipt of the OARRS report
in the patient record, as follows:
(1) Initial
reports requested shall cover at least the twelve months immediately preceding
the date of the request;
(2)
Subsequent reports requested shall, at a minimum, cover the period from the
date of the last report to present;
(3) If the dentist practices primarily in a
county of this state that adjoins another state, the dentist or their delegate
shall also request a report of any information available in the drug database
that pertains to prescriptions issued or drugs furnished to the patient in the
state adjoining that county; and
(4) If an OARRS report regarding the patient
is not available, the dentist shall document in the patient's record the reason
that the report is not available and any efforts made in follow-up to obtain
the requested information.
(G) Exceptions: a dentist shall not be
required to review and assess an OARRS report when prescribing or personally
furnishing an opioid analgesic, benzodiazepine, or other reported drug under
the following circumstances:
(1) The reported
drug is prescribed or personally furnished to a hospice patient in a hospice
care program as those terms are defined in section
3712.01 of the Revised Code, or
any other patient diagnosed as terminally ill;
(2) The reported drug is prescribed for
administration in a hospital, nursing home, or residential care
facility;
(3) The reported drug is
prescribed or personally furnished in an amount indicated for a period not to
exceed seven days;
(4) The reported
drug is prescribed or personally furnished for the treatment of cancer or
another condition associated with cancer; and
(5) The reported drug is prescribed or
personally furnished to treat acute pain resulting from a surgical or other
invasive procedure or a delivery.
Notes
Promulgated Under: 119.03
Statutory Authority: 4715.302
Rule Amplifies: 4715.30, 4715.302
Prior Effective Dates: 01/10/2012, 09/12/2016
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.